Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

ABSTRACT:

Purpose

One of the hallmarks of cancer immunotherapy is the long duration of responses, evident with cytokines like interleukin-2 or a variety of cancer vaccines. However, there is limited information available on very long term outcomes of patients treated with anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibodies. Tremelimumab is an anti-CTLA-4 antibody of immunoglobulin G2 (IgG2) isotype initially tested in patients with advanced melanoma over 12 years ago.

Methods

We reviewed the outcomes of patients with advanced melanoma enrolled in four phase 1 and 2 tremelimumab trials at two sites to determine response rates and long-term survival.

Results

A total of 143 patients were enrolled at two institutions from 2002 to 2008. Tremelimumab administration v

SUBMITTER: Eroglu Z 

PROVIDER: S-EPMC4821004 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature